Wegovy (semaglutide) and Saxenda (liraglutide) are injectable medications approved by the Food and Drug Administration (FDA) for weight loss. Both medications belong to a class of drugs called ...

Saxenda was approved by the FDA for weight loss in 2014, while Wegovy was approved in 2021. The study did not include Eli ...

Novo Nordisk already sells an older, once-daily injectable drug for obesity – Saxenda (liraglutide) – but has said the less frequent dosing required with Wegovy will unlock a much bigger market.

Wegovy (semaglutide), a once-weekly GLP-1 agonist, has already overtaken Novo Nordisk's once-daily obesity therapy Saxenda (liraglutide) in terms of the number of physicians prescribing the two drugs.